Oncotelic Therapeutics Inc. (OTC:OTLC), the RNA-based therapeutics company, says it is making progress advancing its antisense oligonucleotide (ASO) platform, fueled by promising clinical data and ...
The collaboration initially will focus on developing an mRNA therapy for a type of lung fibrosis and an ASO for Lamb-Shaffer syndrome.
Antisense oligonucleotides (ASOs), used to treat genetic diseases, can affect how cells repair damage to their DNA. This is ...
AntiClastic™ Antisense Oligonucleotide (AntiClastic ASO) is a proprietary platform available exclusively through partnerships with Alloy. Sudhir Agrawal, D.Phil, inventor of the underlying IP for the ...
PALO ALTO, Calif. & SAN DIEGO--(BUSINESS WIRE)--n-Lorem, a nonprofit foundation, and GondolaBio, a clinical-stage biotechnology company founded in 2024 and dedicated to developing novel medicines for ...
A recent study involving researchers from the University of Basel reveals that slowing down the intracellular transport of RNA-based drugs can significantly enhance their effectiveness. These ...
CAMP4 to receive $17.5 million upfront and eligible for additional milestone-based payments, in addition to tiered royalties CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results